UNCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Unicycive Therapeutics Inc (UNCY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and future catalysts, the current financial performance and lack of immediate positive signals make it a hold for now.
The MACD is slightly positive, suggesting mild bullish momentum. RSI is neutral at 54.143, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support and resistance levels indicate a narrow trading range with a pivot at 6.874. Overall, the technical indicators do not strongly suggest a significant price movement in the short term.
Analyst coverage from WestPark Capital with a Buy rating and a $72 price target indicates significant long-term potential. Upcoming catalysts include a likely PDUFA approval in June 2026, market launch of a best-in-class drug in Q3 2026, and TDAPA reimbursement support starting January 2027.
EPS has also declined YoY.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of $6.01M, which improved by 46.75% YoY. However, EPS dropped by -28.26% YoY to -0.33, indicating ongoing financial struggles.
WestPark Capital initiated coverage with a Buy rating and a $72 price target, citing significant stock appreciation potential ahead of key milestones in 2026 and 2027.
